CRYOSITE LIMITED — Board/Management Information 2016

Jun 7, 2016

==> picture [595 x 78] intentionally omitted <==

ASX RELEASE Date: 8th June 2016

Subject: Appointment of Chief Executive Officer

The Company is pleased to announce the appointment of Mr Andrew Shine as Chief Executive Officer for Cyrosite Ltd. Andrew will commence at Cryosite on Tuesday 14th June 2016. Andrew will report to the Board and will be accountable for the strategic planning, business development, company operations and financial results of our company. Andrew joins us with a stellar portfolio of health services experience having worked with Monash IVF, Icon Cancer Care, Virtus Health all in Australia and Trinity Biotech in the UK. Andrew is trained as a scientist and has additional business qualifications in Marketing.

Andrews remuneration package consists of a total package (including superannuation) of $220,000. At the Boards discretion, Andrew will be eligible for short term and long term incentives.

The Board also wishes to thank Graeme Moore for his efforts for taking on the additional role as interim CEO since September 2015. Graeme’s role will now revert to his previous position as Executive Director – Operations.

Stephen Roberts Chairman

About Cryosite:

Cryosite pioneered private cord blood banking in Australia, providing parents with the first TGA licensed private cord blood service in 2002, the first TGA licensed Family cord blood bank in 2012, and today is the only bank to offer patented and validated cord tissue banking options. Cryosite has been fully licensed by the TGA since 2002, and is the only family bank to be accredited by NATA (ISO17025, ISO15189).

Cryosite is Australia’s ONLY publically listed cord blood bank, meaning that its financial position is ALWAYS made available to parents.

==> picture [595 x 65] intentionally omitted <==